282 related articles for article (PubMed ID: 25372847)
21. Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
Shi Y; Liu S; Zhu J; Hong T
J Diabetes; 2021 Apr; 13(4):353-357. PubMed ID: 33325105
[TBL] [Abstract][Full Text] [Related]
22. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
[TBL] [Abstract][Full Text] [Related]
23. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
24. Dulaglutide for the treatment of type 2 diabetes.
Amblee A
Drugs Today (Barc); 2014 Apr; 50(4):277-89. PubMed ID: 24918645
[TBL] [Abstract][Full Text] [Related]
25. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
Hussar DA; Wetty DR
J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
[No Abstract] [Full Text] [Related]
26. Dulaglutide: first global approval.
Sanford M
Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
[TBL] [Abstract][Full Text] [Related]
27. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
Tamaki C; Takeuchi M; Iwamoto N; Glaesner W
Nihon Yakurigaku Zasshi; 2015 Oct; 146(4):215-24. PubMed ID: 26656966
[No Abstract] [Full Text] [Related]
30. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
Lorenz M; Evers A; Wagner M
Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
[TBL] [Abstract][Full Text] [Related]
31. GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL; Garber A
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
[TBL] [Abstract][Full Text] [Related]
32. ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
Morey-Vargas OL; Shah P
Ann Intern Med; 2014 Nov; 161(10):JC9. PubMed ID: 25402542
[No Abstract] [Full Text] [Related]
33. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
34. A Clinical Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists.
Unger J
J Fam Pract; 2018 Jun; 67(6 suppl):S1-S2. PubMed ID: 29912994
[No Abstract] [Full Text] [Related]
35. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
Umpierrez GE; Blevins T; Rosenstock J; Cheng C; Anderson JH; Bastyr EJ;
Diabetes Obes Metab; 2011 May; 13(5):418-25. PubMed ID: 21251180
[TBL] [Abstract][Full Text] [Related]
36. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
St Onge EL; Miller SA
Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
[TBL] [Abstract][Full Text] [Related]
37. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
38. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
Vinagre I; Gerstein H; Viñals C; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
[No Abstract] [Full Text] [Related]
39. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
[TBL] [Abstract][Full Text] [Related]
40. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
